Imagion Biosystems Limited

ASX:IBX Stock Report

Market Cap: AU$2.4m

Imagion Biosystems Past Earnings Performance

Past criteria checks 0/6

Imagion Biosystems's earnings have been declining at an average annual rate of -21.4%, while the Medical Equipment industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 15.4% per year.

Key information

-21.4%

Earnings growth rate

23.8%

EPS growth rate

Medical Equipment Industry Growth5.8%
Revenue growth rate15.4%
Return on equityn/a
Net Margin-252.3%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Here's Why We're Watching Imagion Biosystems' (ASX:IBX) Cash Burn Situation

Dec 13
Here's Why We're Watching Imagion Biosystems' (ASX:IBX) Cash Burn Situation

Here's Why We're Watching Imagion Biosystems' (ASX:IBX) Cash Burn Situation

Aug 30
Here's Why We're Watching Imagion Biosystems' (ASX:IBX) Cash Burn Situation

We're Not Very Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Rate

Feb 22
We're Not Very Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Rate

We're Hopeful That Imagion Biosystems (ASX:IBX) Will Use Its Cash Wisely

Sep 09
We're Hopeful That Imagion Biosystems (ASX:IBX) Will Use Its Cash Wisely

We're Not Very Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Rate

May 03
We're Not Very Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Rate

Imagion Biosystems (ASX:IBX) Has Rewarded Shareholders With An Exceptional 582% Total Return On Their Investment

Feb 28
Imagion Biosystems (ASX:IBX) Has Rewarded Shareholders With An Exceptional 582% Total Return On Their Investment

Here's Why We're Not Too Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Situation

Jan 06
Here's Why We're Not Too Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Situation

Revenue & Expenses Breakdown
Beta

How Imagion Biosystems makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:IBX Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 235-13100
30 Sep 234-12100
30 Jun 233-1290
31 Mar 233-1190
31 Dec 223-1080
30 Sep 222-1070
30 Jun 220-1060
31 Mar 222-860
31 Dec 213-660
30 Sep 213-660
30 Jun 213-560
31 Mar 213-550
31 Dec 203-550
30 Sep 203-540
30 Jun 202-440
31 Mar 202-440
31 Dec 192-330
30 Sep 192-440
30 Jun 192-550
31 Mar 191-750
31 Dec 180-860
30 Sep 180-861
30 Jun 180-861
31 Mar 180-852
31 Dec 170-852
31 Dec 160-1216
31 Dec 150-404
31 Dec 140-302

Quality Earnings: IBX is currently unprofitable.

Growing Profit Margin: IBX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IBX is unprofitable, and losses have increased over the past 5 years at a rate of 21.4% per year.

Accelerating Growth: Unable to compare IBX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IBX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: IBX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.